Betiatide Dosage

Usual Adult Dose for Diagnostic

Usual dose: 185 MBq to 370 MBq (5 mCi to 10 mCi) as an intravenous bolus injection

Comments:

• Refer to manufacturer product information for radiation dosimetry.
• Take necessary safety precautions while handling this drug to reduce radiation exposure.
• Only healthcare professionals who have received specialized training and have been authorized by the relevant government agency to handle radionuclides should be allowed to use and manage radiopharmaceuticals safely.
• While preparing and handling injection, use suitable safety measures such as waterproof gloves and effective radiation shielding.
• Patients should be advised to drink enough water to maintain proper hydration before taking the injection. Additionally, they should continue drinking water and urinating frequently after the injection to minimize radiation exposure.

Use: Diagnosis of congenital and acquired renal abnormalities, renal failure, urinary tract obstruction, and calculi in adults and pediatric patients aged 30 days and older

Usual Pediatric Dose for Diagnostic

Usual dose: 2.6 MBq/kg to 5.2 MBq/kg (0.07 mCi/kg to 0.14 mCi/kg) of actual body weight with a minimum dose of 37 MBq (1 mCi) as an intravenous bolus injection

Comments:

• Refer to manufacturer product information for radiation dosimetry.
• Take necessary safety precautions while handling this drug to reduce radiation exposure.
• Only healthcare professionals who have received specialized training and have been authorized by the relevant government agency to handle radionuclides should be allowed to use and manage radiopharmaceuticals safely.
• While preparing and handling this injection, use suitable safety measures such as waterproof gloves and effective radiation shielding.
• Patients should be advised to drink enough water to maintain proper hydration before taking the injection. Additionally, they should continue drinking water and urinating frequently after the injection to minimize radiation exposure.

Use: Diagnosis of congenital and acquired renal abnormalities, renal failure, urinary tract obstruction, and calculi in adults and pediatric patients aged 30 days and older

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in pediatric patients younger than 30 days.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This product is for intravenous injection only.
• Before administering the dose, use a suitable radioactivity calibration system to measure the patient's dose.
• Before administering the injection, visually examine the prepared solution for discoloration or particulate matter behind a lead glass shield. Only use solutions that are clear and do not contain any visible particles.
• When withdrawing doses for patient administration, use a shielded syringe and aseptic techniques. During the administration procedure, wear waterproof gloves.

Storage requirements:

• Before radiolabeling, store at a controlled room temperature 20C to 25C (68F to 77F) and protect from light.
• Following radiolabeling with sodium pertechnetate Tc 99m injection, store the vial in an upright position within a shielding material to protect against radiation exposure. Keep the vial at a room temperature range of 15C to 30C (59F to 86F) and use it within 6 hours of radiolabeling.
• Dispose of any unused Technetium Tc 99m Mertiatide Injection in accordance with the regulations of the government agency authorized to license the use of this radionuclide.
• This preparation is authorized for use by individuals licensed by the Nuclear Regulatory Commission or the pertinent regulatory body of an Agreement State.

Reconstitution/preparation techniques:

• Refer to manufacturer product information for detailed information on preparation and dose calculation.

Patient advice:

• Patients should be advised to maintain proper hydration by drinking enough water before taking the injection. Furthermore, they should continue to drink water and urinate frequently after the injection to minimize radiation exposure.
• Inform pregnant women about the potential risk of fetal exposure to radiation doses if they undergo a radionuclide procedure.
• To minimize radiation exposure to a breastfed infant, advise a lactating woman to temporarily halt breastfeeding and pump and discard breast milk for at least 24 hours after administration.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer